Ann: MedAdvisor to Acquire Healthnotes to Accelerate Growth-MDR.AX, page-15

First 15 Last

Share
Profile

Follow
LeBigMac

735 Posts.

13

31/08/16

10:00

Post #: 18814029
Share

Originally posted by pintohoo ↑

the unseen advantage here is the large leap on others -

this is a very specific market and the chomp that MDR have has now gotten a whole lot bigger in one bite - that makes it very hard for someone else to enter.

Also - it makes it very very hard for another player who is in the field and will be faced with customer after customer coming into their chemist shop and asking if they do Medadvisor

Combine this ann. on health notes and the Diabetes announcement - and, IMO

this is a combined hit that will really hurt any other players.

If they are not thinking about capitulating already - they should certainly sit down and think it through now.

MDR has the app. that is better - now has the scale and will soon have a herd of GP's on board.

Any competitor should really start to think about getting on board here - as if they do - it will just make the thing unassailable.

This IMO is a very low level investment (early stage) - and, it just got derisked a lot.

all my opinion in a huge market

Pinto

Expand

Hey Pinto, at what percentage do you think MDR will achieve critical mass of market share?

MDR Price at posting: 3.6¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

First 15 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 8.0¢		Change 0.001(1.27%)		Mkt cap ! $49.98M

Open	High	Low	Value	Volume
7.8¢	8.0¢	7.7¢	$65.41K	833.4K

Buyers (Bids)

No.	Vol.	Price($)
2	115265	7.9¢

Sellers (Offers)

Price($)	Vol.	No.
8.0¢	44541	2

View Market Depth

No.	Vol.	Price($)
2	115265	0.079
1	78905	0.078
2	114851	0.077
1	200000	0.076
6	127452	0.075

Price($)	Vol.	No.
0.080	44541	2
0.082	110111	1
0.083	105000	1
0.085	32040	1
0.086	210000	1

Last trade - 12.37pm 27/06/2025 (20 minute delay)

MDR (ASX) Chart

Ann: MedAdvisor to Acquire Healthnotes to Accelerate Growth-MDR.AX, page-15

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Australia’s gas crisis is here – and dying coal plants aren’t helping

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: MedAdvisor to Acquire Healthnotes to Accelerate Growth-MDR.AX, page-15

Top Stories

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Australia’s gas crisis is here – and dying coal plants aren’t helping

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News